A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

Trial Details

NCT ID
NCT06764771
Phase
PHASE1
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • BMS-986488
  • Adagrasib
  • Cetuximab
  • Nivolumab
Locations (sample)
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Allentown, Pennsylvania, United States|40.60843,-75.49018
  • Germantown, Tennessee, United States|35.08676,-89.81009
  • Dallas, Texas, United States|32.78306,-96.80667
  • Brisbane, Queensland, Australia|-27.46794,153.02809

Key Eligibility Criteria

  • Participant must be ≥ 18 years of age.
  • Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
  • Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), an…
  • Parts 2A, 1D, 2D: ccRCC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →